“Claims about the benefits of using CBD on viral infections were largely supported by CBD online retailers and most often appear to be a biased interpretation of the scientific literature or a dishonest manipulation of the information for commercial purposes.”
The National Organization for the Reform of Marijuana Laws wishes to reiterate its message that cannabis consumers and others beware of online misinformation surrounding the use of either whole-plant cannabis or CBD as a potential remedy for the COVID-19 virus.
The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine.
Representatives of the US Food and Drug Administration issued warning letters on Monday to multiple companies for marketing CBD-specific products in ways that violate federal law.
CBD-infused products sold online frequently possess significantly lower percentages of CBD than advertised, according to a report published by the online watchdog group LegitScript.com. Investigators lab-tested 30 CBD products obtained from leading online retailers. Twenty of the thirty products possessed significant deviations in CBD content as compared to what was advertised. Sixteen of the 20 products contained lower percentages of CBD than the amount stated on the product’s label — a finding that is consistent with prior analyses. Some of the products also tested positive for the presence of solvent residue and elevated levels of heavy metals – findings that are also consistent with those of other studies. Authors also evaluated the marketing practices of 300 leading online CBD retailers….
Commercially marketed CBD-infused products are not subject to explicit federal regulations. As a result, third-party lab testing has frequently revealed inconsistencies between the percentage of CBD advertised and the amount actually contained in some of these products.
Rather than use these unfortunate incidents as an opportunity to further drive these markets into the shadows, the administration should officially legalize cannabis and empower the FDA to better study, regulate, and oversee these emerging THC and CBD delivery devices — and to create regulatory standards for legal states to follow and enforce.
Members of the US Senate Committee on Agriculture, Nutrition, and Forestry will hear expert testimony next week regarding the production of industrial hemp and hemp-derived products.
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. Commenting on the study’s findings, NORML Deputy Director Paul Armentano said, “These conclusions add to the growing body of evidence that cannabis and its constituents represent an exit away from the use or abuse of other controlled substances rather than a supposed ‘gateway.'”
NORML has submitted written comments to the US Food and Drug Administration ahead of the agency’s scheduled hearing on the regulation CBD-infused products. The agency will be taking in person public testimony on Friday, May 31, with regard to the “manufacturing, product quality, marketing, labeling, and sale” of CBD-infused retail products.